ALK Abello shares dip as profit slumps

6 February 2018

Danish allergy immunotherapy specialist ALK Abello (ALKB: DC) today released financial results, showing that sales in the fourth quarter of 2017 were up 1.2% at 763 million Danish kroner ($127.6 million), +4% in local currencies, with operating profit down 36.5% at 61 million kroner, with the news sending the firm’s share 2.66% lower at 696.00 kroner.

There was a 59% growth in tablet sales: strong European growth and first Acarizax (HDM SLIT) sales in North America.Sales of legacy SCIT and SLIT-drops products continued to be weakened by supply constraints.

For full-year 2017, the company said that overall performance was as expected and in line with guidance, mainly reflecting market normalizations in Europe after the market disruptions, which boosted ALK revenue and operating profit to record-highs in 2016. Earnings were as anticipated impacted by significant investments in the build-up in North America, in retaining market leadership in Europe, in the roll-out of Acarizax and in establishing a robust product supply chain:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK